ARDX
Price
$4.71
Change
+$0.10 (+2.17%)
Updated
Jul 10, 04:59 PM (EDT)
Capitalization
1.1B
21 days until earnings call
CLRB
Price
$4.91
Change
+$0.06 (+1.24%)
Updated
Jul 10, 04:58 PM (EDT)
Capitalization
13.86M
39 days until earnings call
Interact to see
Advertisement

ARDX vs CLRB

Header iconARDX vs CLRB Comparison
Open Charts ARDX vs CLRBBanner chart's image
Ardelyx
Price$4.71
Change+$0.10 (+2.17%)
Volume$71.86K
Capitalization1.1B
Cellectar Biosciences
Price$4.91
Change+$0.06 (+1.24%)
Volume$500
Capitalization13.86M
ARDX vs CLRB Comparison Chart in %
Loading...
ARDX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
CLRB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ARDX vs. CLRB commentary
Jul 11, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ARDX is a Buy and CLRB is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 11, 2025
Stock price -- (ARDX: $4.60 vs. CLRB: $4.85)
Brand notoriety: ARDX and CLRB are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ARDX: 128% vs. CLRB: 19%
Market capitalization -- ARDX: $1.1B vs. CLRB: $13.86M
ARDX [@Biotechnology] is valued at $1.1B. CLRB’s [@Biotechnology] market capitalization is $13.86M. The market cap for tickers in the [@Biotechnology] industry ranges from $314.48B to $0. The average market capitalization across the [@Biotechnology] industry is $2.43B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ARDX’s FA Score shows that 0 FA rating(s) are green whileCLRB’s FA Score has 0 green FA rating(s).

  • ARDX’s FA Score: 0 green, 5 red.
  • CLRB’s FA Score: 0 green, 5 red.
According to our system of comparison, ARDX is a better buy in the long-term than CLRB.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ARDX’s TA Score shows that 4 TA indicator(s) are bullish while CLRB’s TA Score has 4 bullish TA indicator(s).

  • ARDX’s TA Score: 4 bullish, 5 bearish.
  • CLRB’s TA Score: 4 bullish, 6 bearish.
According to our system of comparison, ARDX is a better buy in the short-term than CLRB.

Price Growth

ARDX (@Biotechnology) experienced а +9.79% price change this week, while CLRB (@Biotechnology) price change was +2.54% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +9.89%. For the same industry, the average monthly price growth was +16.25%, and the average quarterly price growth was +20.89%.

Reported Earning Dates

ARDX is expected to report earnings on Oct 30, 2025.

CLRB is expected to report earnings on Aug 18, 2025.

Industries' Descriptions

@Biotechnology (+9.89% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ARDX($1.1B) has a higher market cap than CLRB($13.9M). ARDX YTD gains are higher at: -9.270 vs. CLRB (-45.931). ARDX has higher annual earnings (EBITDA): -28.23M vs. CLRB (-45.92M). CLRB has less debt than ARDX: CLRB (474K) vs ARDX (155M). ARDX has higher revenues than CLRB: ARDX (362M) vs CLRB (0).
ARDXCLRBARDX / CLRB
Capitalization1.1B13.9M7,921%
EBITDA-28.23M-45.92M61%
Gain YTD-9.270-45.93120%
P/E RatioN/AN/A-
Revenue362M0-
Total Cash214MN/A-
Total Debt155M474K32,700%
FUNDAMENTALS RATINGS
ARDX vs CLRB: Fundamental Ratings
ARDX
CLRB
OUTLOOK RATING
1..100
2660
VALUATION
overvalued / fair valued / undervalued
1..100
97
Overvalued
57
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
96100
PRICE GROWTH RATING
1..100
5397
P/E GROWTH RATING
1..100
5277
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CLRB's Valuation (57) in the Biotechnology industry is somewhat better than the same rating for ARDX (97). This means that CLRB’s stock grew somewhat faster than ARDX’s over the last 12 months.

CLRB's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as ARDX (100). This means that CLRB’s stock grew similarly to ARDX’s over the last 12 months.

ARDX's SMR Rating (96) in the Biotechnology industry is in the same range as CLRB (100). This means that ARDX’s stock grew similarly to CLRB’s over the last 12 months.

ARDX's Price Growth Rating (53) in the Biotechnology industry is somewhat better than the same rating for CLRB (97). This means that ARDX’s stock grew somewhat faster than CLRB’s over the last 12 months.

ARDX's P/E Growth Rating (52) in the Biotechnology industry is in the same range as CLRB (77). This means that ARDX’s stock grew similarly to CLRB’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ARDXCLRB
RSI
ODDS (%)
Bearish Trend 2 days ago
88%
Bullish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
87%
Bullish Trend 2 days ago
83%
Momentum
ODDS (%)
Bullish Trend 2 days ago
81%
Bearish Trend 2 days ago
86%
MACD
ODDS (%)
N/A
Bearish Trend 2 days ago
77%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
83%
Bearish Trend 2 days ago
88%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
84%
Bearish Trend 2 days ago
85%
Advances
ODDS (%)
Bullish Trend 2 days ago
86%
Bullish Trend 17 days ago
83%
Declines
ODDS (%)
Bearish Trend about 1 month ago
82%
Bearish Trend 9 days ago
85%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
83%
Bullish Trend 2 days ago
87%
Aroon
ODDS (%)
Bearish Trend 2 days ago
79%
Bearish Trend 2 days ago
88%
View a ticker or compare two or three
Interact to see
Advertisement
ARDX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
CLRB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
DFSGX24.620.14
+0.57%
DF Dent Small Cap Growth Institutional
JFARX38.27N/A
N/A
JHancock Fundamental All Cap Core R4
AMVYX16.16N/A
N/A
American Century Mid Cap Value Y
NWABX32.53N/A
N/A
Nationwide R6
FTMSX25.70N/A
N/A
FullerThaler Behvrl Mcr-Cp Eq Instl

ARDX and

Correlation & Price change

A.I.dvisor indicates that over the last year, ARDX has been loosely correlated with VCYT. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if ARDX jumps, then VCYT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ARDX
1D Price
Change %
ARDX100%
+2.68%
VCYT - ARDX
45%
Loosely correlated
+1.88%
PCVX - ARDX
35%
Loosely correlated
+6.93%
RNAC - ARDX
35%
Loosely correlated
+21.86%
CGEN - ARDX
33%
Poorly correlated
-1.76%
CLRB - ARDX
31%
Poorly correlated
+3.19%
More

CLRB and

Correlation & Price change

A.I.dvisor indicates that over the last year, CLRB has been closely correlated with QTTB. These tickers have moved in lockstep 72% of the time. This A.I.-generated data suggests there is a high statistical probability that if CLRB jumps, then QTTB could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CLRB
1D Price
Change %
CLRB100%
+3.19%
QTTB - CLRB
72%
Closely correlated
+8.63%
IBRX - CLRB
41%
Loosely correlated
+2.95%
ADCT - CLRB
40%
Loosely correlated
+9.76%
CELC - CLRB
37%
Loosely correlated
+0.82%
ANAB - CLRB
37%
Loosely correlated
+6.14%
More